Study of Triple Therapy with Metformin, SGLT-2 Inhibitor, and GLP-1 Receptor Agonist Compared to Other Oral Diabetes Medications in Adults with Type 2 Diabetes and Poor Blood Sugar Control

What this Trial Is About

Researchers are studying the safety and effectiveness of a triple combination therapy using Metformin, an SGLT-2 inhibitor Ganagliflozin, and a GLP-1 receptor agonist Liraglutide compared to other oral antidiabetic drugs in adults with type 2 diabetes who have poor blood sugar control. This phase 4 trial focuses on patients whose blood sugar levels remain high despite previous treatments. The aim is to determine how well these therapies work and how safe they are for this group. The trial compares two groups one receiving Metformin combined with Ganagliflozin and Liraglutide, and the other continuing a triple oral therapy with other antidiabetic drugs excluding SGLT-2 inhibitors and oral GLP-1 receptor agonists. Dosing follows prior stable regimens with specific dosing for Ganagliflozin 50 mg daily and Liraglutide starting at 0.6 mg daily and increasing over three weeks. Treatment lasts for 24 weeks. Participants will have their blood sugar control monitored through HbA1c measurements at baseline and after 24 weeks, along with other health indicators such as blood pressure, cholesterol, waist and hip size, fasting glucose, insulin resistance, urine tests, body mass index, and waist-to-height ratio. Safety and treatment effects will be assessed throughout the study, with all outcomes measured at week 24. The study runs until mid-2028.

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control